GLPG

Galapagos N.V. NASDAQ

Healthcare ·Biotechnology ·BE · glpg.com

$28.46

Mkt Cap $1.9B

52w Low $24.74 28.5% of range 52w High $37.78

50d MA $30.78 200d MA $32.21

P/E (TTM) 5.8x

EV/EBITDA 3.2x

P/B 0.6x

Debt/Equity 0.0x

ROE —

P/FCF -9.1x

RSI (14) —

ATR (14) —

Beta 0.15

50d MA $30.78

200d MA $32.21

Avg Volume 142.8K

About

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondyl…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 23, 2026	AMC	1.00	16.38	+1538.0%	33.87	+5.5%	+1.4%	+0.4%	-1.1%	-0.6%	+0.6%	-9.5%	—
Nov 5, 2025	AMC	-0.20	-3.59	-1696.3%	29.89	+1.7%	+4.4%	+5.5%	+8.6%	+9.9%	+8.1%	+5.7%	—
Jul 23, 2025	AMC	-0.67	-1.89	-182.3%	33.29	-13.4%	-7.3%	-1.9%	-1.5%	-1.4%	-0.1%	-3.9%	—
Apr 23, 2025	AMC	-0.23	-2.47	-973.9%	25.50	+0.2%	+3.9%	+5.3%	+5.4%	+5.6%	+5.6%	+12.7%	—
Feb 28, 2025	AMC	-0.24	0.39	+263.3%	26.08	+2.5%	-0.3%	-1.3%	-0.1%	+1.8%	+1.9%	-3.7%	—
Oct 30, 2024	AMC	-0.27	-0.77	-185.2%	28.59	-5.8%	-7.5%	-5.9%	-6.6%	-6.5%	-5.6%	-3.3%	—
Sep 12, 2024	AMC	0.03	0.14	+450.3%	29.30	+0.5%	+2.9%	+4.7%	+4.3%	+3.3%	+3.9%	-0.1%	—
May 2, 2024	AMC	-0.12	0.39	+425.0%	29.45	-1.2%	-1.2%	+0.1%	-1.3%	-1.4%	-2.3%	-5.9%	—
Feb 23, 2024	AMC	-1.18	2.39	+302.5%	36.24	-0.0%	+0.7%	+1.4%	-0.4%	-3.1%	-3.1%	-9.8%	—
Nov 3, 2023	AMC	-0.62	0.39	+162.9%	37.06	+5.0%	+2.8%	+2.7%	-1.0%	-2.2%	-1.9%	+3.5%	—
Aug 3, 2023	AMC	-0.70	0.08	+111.4%	42.20	+4.2%	+0.4%	-4.2%	-7.6%	-8.2%	-5.9%	-11.8%	—
May 4, 2023	AMC	-0.87	0.43	+149.4%	40.50	+2.9%	+5.9%	+3.7%	+3.3%	+3.5%	+1.7%	+3.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 25	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$34.36	$34.42	+0.2%	-1.0%	-2.5%	-2.0%	-0.8%	-3.8%
Nov 7	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$31.20	$31.91	+2.3%	+1.1%	+4.0%	+5.3%	+3.6%	+0.9%
Oct 22	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$31.43	$32.19	+2.4%	+1.4%	+1.9%	+1.7%	-1.2%	-0.3%
Oct 21	Leerink Partners	Upgrade	Market Perform → Outperform	—	$34.39	$32.05	-6.8%	-8.6%	-7.3%	-6.9%	-7.1%	-9.7%
Feb 14	Morgan Stanley	Downgrade	Equal Weight → Underweight	—	$25.49	$25.15	-1.3%	-0.2%	+4.1%	+4.7%	+4.9%	+4.9%
Jan 23	Barclays	Downgrade	Equal Weight → Underweight	—	$23.93	$23.56	-1.5%	-0.8%	-1.0%	-1.3%	-1.8%	-3.2%
Nov 1	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$26.44	$26.75	+1.2%	+1.7%	+1.0%	+1.1%	+2.1%	+3.9%
Apr 22	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$29.08	$28.96	-0.4%	-0.0%	+1.3%	-1.1%	-1.5%	-1.1%
Apr 1	BofA Securities	Downgrade	Neutral → Underperform	—	$32.20	$32.06	-0.4%	+0.9%	-1.3%	-1.3%	-1.2%	-1.2%
Mar 28	BofA Securities	Downgrade	Neutral → Underperform	—	$32.95	$32.18	-2.3%	-2.3%	-1.4%	-3.6%	-3.5%	-3.5%
Jan 2	BofA Securities	Maintains	Neutral → Neutral	—	$40.65	$40.60	-0.1%	+1.7%	+1.3%	+1.9%	+1.6%	+4.4%
Aug 7	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$42.36	$42.42	+0.1%	-4.6%	-8.0%	-8.5%	-6.3%	-7.2%
Aug 1	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$42.35	$42.00	-0.8%	-0.8%	-1.3%	-0.4%	+0.0%	-4.5%
Jul 31	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$41.82	$41.57	-0.6%	+1.3%	+0.5%	-0.1%	+0.9%	+1.3%
Jul 24	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$42.98	$42.48	-1.2%	-2.1%	-4.2%	-4.5%	-6.0%	-2.7%
Jul 17	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$41.79	$42.34	+1.3%	+0.3%	+1.7%	+2.1%	+1.9%	+2.8%
Jun 26	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$41.00	$41.22	+0.5%	-1.1%	-0.2%	-1.7%	-1.5%	-0.8%
Jun 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$43.04	$41.40	-3.8%	-1.9%	-2.2%	-3.3%	-1.3%	-1.5%
May 31	JP Morgan	Maintains	Neutral → Neutral	—	$42.14	$41.35	-1.9%	-1.9%	-2.7%	-1.6%	-0.7%	+0.6%
May 9	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$41.99	$41.18	-1.9%	-0.3%	-0.2%	-2.0%	-3.5%	+0.0%
May 8	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$42.89	$42.60	-0.7%	-2.1%	-2.4%	-2.3%	-4.0%	-5.5%
May 8	Raymond James	Upgrade	Market Perform → Outperform	—	$42.89	$42.60	-0.7%	-2.1%	-2.4%	-2.3%	-4.0%	-5.5%
Feb 27	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$38.19	$38.03	-0.4%	-1.2%	-1.8%	-1.5%	-4.0%	-3.5%
Feb 27	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$38.19	$38.03	-0.4%	-1.2%	-1.8%	-1.5%	-4.0%	-3.5%
Jan 23	Jefferies	Upgrade	Underperform → Hold	—	$45.82	$47.06	+2.7%	+0.9%	-1.7%	-2.8%	-2.7%	-3.6%
Nov 7	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$42.75	$41.09	-3.9%	-3.5%	-3.8%	-6.2%	-3.0%	-2.2%
Nov 7	Raymond James	Downgrade	Outperform → Market Perform	—	$42.75	$41.09	-3.9%	-3.5%	-3.8%	-6.2%	-3.0%	-2.2%
Nov 7	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$42.75	$41.09	-3.9%	-3.5%	-3.8%	-6.2%	-3.0%	-2.2%
Oct 13	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$42.10	$41.90	-0.5%	+2.6%	+3.3%	+5.9%	+8.3%	+4.3%
Sep 9	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$48.57	$48.80	+0.5%	-0.8%	+7.0%	+1.3%	+0.8%	+0.1%
Aug 15	Morgan Stanley	Maintains	Overweight → Overweight	—	$54.25	$54.56	+0.6%	+1.7%	+0.7%	-1.1%	-3.7%	-3.9%
Aug 8	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$54.70	$54.56	-0.3%	-1.1%	-2.6%	-0.1%	-1.0%	-0.8%
Jul 15	Morgan Stanley	Maintains	Overweight → Overweight	—	$52.89	$53.32	+0.8%	+1.7%	+2.1%	+7.1%	+6.7%	+6.4%
May 9	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$59.66	$59.31	-0.6%	-5.2%	-3.2%	-5.1%	-4.0%	-0.7%
Feb 28	Morgan Stanley	Maintains	Overweight → Overweight	—	$65.74	$65.39	-0.5%	+0.7%	+0.9%	-2.0%	-5.7%	-6.5%
Jan 27	Citigroup	Upgrade	Neutral → Buy	—	$53.32	$61.63	+15.6%	+22.5%	+26.5%	+26.6%	+28.5%	+23.2%
Jan 6	Morgan Stanley	Maintains	Overweight → Overweight	—	$51.75	$52.09	+0.7%	+0.2%	+0.1%	-0.8%	+1.3%	+0.6%
Nov 8	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$54.28	$55.96	+3.1%	+5.2%	+4.0%	+0.0%	-1.6%	-2.7%
Aug 19	Barclays	Downgrade	Overweight → Equal Weight	—	$59.07	$57.78	-2.2%	-4.4%	-6.2%	-3.0%	-3.3%	-3.5%
Aug 9	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$60.14	$58.87	-2.1%	-1.1%	-1.6%	-2.7%	-2.1%	-2.4%
May 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$75.04	$71.11	-5.2%	-2.0%	-1.9%	-1.2%	+1.4%	+1.5%
Apr 14	Barclays	Upgrade	Equal Weight → Overweight	—	$78.30	$81.51	+4.1%	+2.8%	+1.4%	+1.1%	+0.7%	+1.7%
Mar 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$82.41	$83.28	+1.1%	+1.3%	-0.0%	+0.8%	-0.6%	-2.2%
Feb 22	Raymond James	Upgrade	Market Perform → Outperform	—	$86.28	$83.56	-3.2%	-0.7%	-1.0%	-1.9%	-1.3%	-4.3%
Jan 19	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$100.01	$106.53	+6.5%	+7.7%	+8.5%	+11.9%	+11.2%	+11.3%
Nov 19	Maxim Group	Maintains	Buy → Buy	—	$123.95	$123.01	-0.8%	-0.5%	+0.6%	+1.0%	-0.3%	-2.6%
Oct 21	Goldman Sachs	Downgrade	Neutral → Sell	—	$131.79	$123.35	-6.4%	-6.6%	-6.2%	-3.1%	-3.4%	-2.9%
Oct 13	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$148.25	$147.01	-0.8%	-1.6%	-3.8%	-6.6%	-13.1%	-12.0%
Aug 25	Jefferies	Downgrade	Buy → Hold	—	$134.83	$129.64	-3.8%	-2.3%	-0.5%	-3.3%	-2.9%	-1.2%
Aug 24	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$137.16	$136.48	-0.5%	-1.7%	-3.9%	-2.2%	-4.9%	-4.5%

Recent Filings

8-K

Artiva Biotherapeutics, Inc. -- 8-K Filing

Artiva Biotherapeutics appointed a new executive with extensive Johnson & Johnson financial leadership experience, including CFO responsibilities, strengthening its senior management team.

Feb 24

Data updated apr 26, 2026 10:41am · Source: massive.com